Phase 1b Open-label Study of MK-7162 in Combination With Pembrolizumab (MK-3475) +/- Other Therapies in Participants With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 19 Aug 2018
At a glance
- Drugs MK-7162 (Primary) ; Pembrolizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 03 Jul 2018 Planned End Date changed from 21 Jun 2019 to 13 Jan 2021.
- 03 Jul 2018 Planned primary completion date changed from 21 Jun 2019 to 13 Jan 2021.
- 12 Dec 2017 Status changed from not yet recruiting to recruiting.